Physician profile
Robert C Levine
NPI 1104815232
$532.64
in general payments reported to CMS, 2019-2025
13 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $134 · 2022: $76.39 · 2023: $53.79 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $78.06 | 2025 | Wegovy |
| Pfizer INC. | $75.15 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $54.30 | 2021 | |
| Abbvie INC. | $47.55 | 2023-2025 | |
| Lilly USA, LLC | $46.25 | 2021-2025 | Zepbound, Mounjaro |
| Janssen Biotech, INC. | $46.23 | 2025 | Tremfya |
| Glaxosmithkline, LLC. | $36.10 | 2025 | Trelegy Ellipta |
| Amgen INC. | $33.06 | 2021-2025 | Otezla, Repatha |
| Exact Sciences Corporation | $32.17 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.20 | 2022 | |
| Novartis Pharmaceuticals Corporation | $25.81 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.43 | 2025 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.